Robert W. Baird Lowers Intuitive Surgical (NASDAQ:ISRG) Price Target to $436.00

Intuitive Surgical (NASDAQ:ISRG) had its price target lowered by equities researchers at Robert W. Baird from $440.00 to $436.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s price target points to a potential upside of 17.01% from the stock’s current price.

Several other analysts have also weighed in on the stock. Piper Sandler boosted their target price on shares of Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research note on Wednesday, January 24th. Truist Financial boosted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Raymond James boosted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Citigroup boosted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Mizuho boosted their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $378.48.

Intuitive Surgical Trading Down 0.4 %

Shares of NASDAQ:ISRG opened at $372.63 on Friday. The company has a fifty day simple moving average of $387.27 and a 200 day simple moving average of $342.60. The firm has a market cap of $132.08 billion, a PE ratio of 74.08, a price-to-earnings-growth ratio of 5.81 and a beta of 1.36. Intuitive Surgical has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 earnings per share. As a group, equities research analysts forecast that Intuitive Surgical will post 4.93 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,373,093.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last three months, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

A number of large investors have recently made changes to their positions in the business. Azzad Asset Management Inc. ADV grew its stake in shares of Intuitive Surgical by 0.3% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 18,952 shares of the medical equipment provider’s stock valued at $7,564,000 after buying an additional 56 shares in the last quarter. Naviter Wealth LLC bought a new stake in shares of Intuitive Surgical in the 1st quarter valued at approximately $200,000. Cullinan Associates Inc. grew its stake in shares of Intuitive Surgical by 300.0% in the 1st quarter. Cullinan Associates Inc. now owns 6,400 shares of the medical equipment provider’s stock valued at $2,554,000 after buying an additional 4,800 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in shares of Intuitive Surgical by 33.5% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 4,260 shares of the medical equipment provider’s stock valued at $1,700,000 after buying an additional 1,070 shares in the last quarter. Finally, Congress Wealth Management LLC DE grew its stake in shares of Intuitive Surgical by 0.5% in the 1st quarter. Congress Wealth Management LLC DE now owns 41,494 shares of the medical equipment provider’s stock valued at $16,560,000 after buying an additional 217 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.